SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed high-grade anal squamous intraepithelial lesions (HSIL) with residual HSIL of the anal canal or margin by high-resolution anoscopy * Declined routine surgery or not a candidate for surgical excision of HSIL * Documented evidence of HIV infection by one of the following methods: * Serologic (ELISA or western blot) * Culture * Quantitative polymerase chain reaction or bDNA assays * HIV RNA no greater than 500 copies/mL * CD4 at least 200 x 10\^6/L * Must have received stable highly active antiviral therapy (HAART) for at least 4 weeks before study * HAART defined as 3 or more agents, including a protease inhibitor or nonnucleoside reverse transcriptase inhibitor that is approved or available through expanded access combination antiviral therapy * No prior history of invasive anal or cervical cancer * No concurrent untreated cervical HSIL PATIENT CHARACTERISTICS: Age * 18 and over Life expectancy * At least 12 months Hematopoietic * Hemoglobin at least 10 g/dL * Platelet count at least 75,000/mm\^3 * Absolute neutrophil count at least 1,000/mm\^3 Hepatic * AST and ALT no greater than 3 times upper limit of normal (ULN) Renal * Creatinine no greater than 1.5 times ULN Immunologic * No prior severe allergic reactions (i.e., anaphylactic response) to drugs or any other allergen * No history of collagen-vascular or autoimmune disorder requiring treatment within the past 5 years * No other concurrent illness that compromises the immune system * No active serious opportunistic infection Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use 2 forms of effective contraception during and for 3 months after study * No concurrent participation in a conception process (e.g., active attempt to become pregnant or impregnate, sperm donation, or in vitro fertilization) * No other concurrent medical or psychiatric illness that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent immunostimulants (including interferon or interleukin-12) Chemotherapy * More than 1 year since prior chemotherapy for cancer Endocrine therapy * No concurrent steroids that compromise immune function * Concurrent topical corticosteroids allowed if dose determined not to suppress immune function Radiotherapy * More than 1 year since prior radiotherapy for cancer Other * More than 30 days since other prior investigational agents * No concurrent medications that suppress immune function